Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Frontera Therapeutics / Equity Capital Markets

<ul>
<li>Frontera, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. UBS and Haitong are the joint book runners.</li>
<li>In this note, we look at the company’s core product FT-003 and FT-002, and assess the selling point around the core products.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Frontera, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. UBS and Haitong are the joint book runners.
In this note, we look at the company’s core product FT-003 and FT-002, and assess the selling point around the core products.
We also look at the company’s pre-IPO investors and management team.


Frontera Pre-IPO：難題を抱える眼科遺伝子治療の新興企業